BCYC Stock - Bicycle Therapeutics plc
Unlock GoAI Insights for BCYC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $35.27M | $26.98M | $14.46M | $11.70M | $10.39M |
| Gross Profit | $-137,691,000 | $-129,520,000 | $14.46M | $11.70M | $-22,759,000 |
| Gross Margin | -390.3% | -480.1% | 100.0% | 100.0% | -219.0% |
| Operating Income | $-209,872,000 | $-189,946,000 | $-116,653,000 | $-65,618,000 | $-51,960,000 |
| Net Income | $-169,031,000 | $-180,664,000 | $-112,717,000 | $-66,819,000 | $-51,010,000 |
| Net Margin | -479.2% | -669.7% | -779.3% | -571.2% | -491.0% |
| EPS | $-2.91 | $-5.08 | $-3.80 | $-2.67 | $-2.66 |
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 24th 2025 | Truist | Initiation | Hold | $19 |
| October 31st 2025 | RBC Capital Mkts | Downgrade | Sector Perform | $11 |
| November 8th 2024 | Stephens | Initiation | Equal Weight | $25 |
| September 6th 2024 | RBC Capital Mkts | Initiation | Outperform | $35 |
| August 7th 2024 | B. Riley Securities | Downgrade | Neutral | $28← $33 |
| September 11th 2023 | B. Riley Securities | Upgrade | Buy | - |
| August 31st 2022 | Cowen | Initiation | Outperform | - |
| July 28th 2022 | Barclays | Initiation | Overweight | $30 |
| July 6th 2022 | Canaccord Genuity | Resumed | Buy | $60 |
| April 13th 2022 | B. Riley Securities | Downgrade | Neutral | $33← $62 |
Earnings History & Surprises
BCYCEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $-1.00 | — | — | — |
Q4 2025 | Oct 30, 2025 | $-1.09 | $-0.85 | +22.0% | ✓ BEAT |
Q3 2025 | Aug 8, 2025 | $-0.95 | $-1.14 | -20.0% | ✗ MISS |
Q2 2025 | May 1, 2025 | $-0.86 | $-0.88 | -2.3% | ✗ MISS |
Q1 2025 | Feb 25, 2025 | $-0.85 | $-0.80 | +5.9% | ✓ BEAT |
Q4 2024 | Oct 31, 2024 | $-0.78 | $-0.74 | +5.1% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-1.10 | $-0.77 | +30.0% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-1.26 | $-0.62 | +50.8% | ✓ BEAT |
Q1 2024 | Feb 20, 2024 | $-1.23 | $-1.16 | +5.7% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-1.06 | $-1.26 | -18.9% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-1.10 | $-1.41 | -28.2% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-1.06 | $-1.30 | -22.6% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $-1.06 | $-1.01 | +4.7% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.98 | $-0.96 | +2.0% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.82 | $-0.90 | -9.8% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.70 | $-0.93 | -32.9% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $-0.60 | $-0.63 | -5.0% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.67 | $-0.59 | +11.9% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.72 | $-0.74 | -2.8% | ✗ MISS |
Latest News
Bicycle Therapeutics Secures Long-Term Nuclear And Industry Partnerships To Support 212Pb Radiopharmaceutical Development And Commercial Supply
📈 PositiveTruist Securities Initiates Coverage On Bicycle Therapeutics with Hold Rating, Announces Price Target of $10
➖ NeutralCitizens Maintains Market Outperform on Bicycle Therapeutics, Raises Price Target to $12
📈 PositiveRBC Capital Downgrades Bicycle Therapeutics to Sector Perform, Lowers Price Target to $11
📉 NegativeBicycle Therapeutics Q3 EPS $(0.85) Beats $(1.09) Estimate, Sales $11.734M Beat $7.333M Estimate
📈 PositiveBicycle Therapeutics Increases Board Size To Ten Directors
➖ NeutralFrequently Asked Questions about BCYC
What is BCYC's current stock price?
What is the analyst price target for BCYC?
What sector is Bicycle Therapeutics plc in?
What is BCYC's market cap?
Does BCYC pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BCYC for comparison